Trial Profile
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Apr 2022
Price :
$35
*
At a glance
- Drugs Arbaclofen (Primary) ; Baclofen
- Indications Muscle spasticity
- Focus Registrational; Therapeutic Use
- Sponsors Osmotica Pharmaceutical; RVL Pharmaceuticals
- 18 Mar 2020 According to Osmotica Pharmaceutical media release, during the second quarter of 2020, the company intends to file an amended NDA for arbaclofen ER, a potential treatment for spasticity in patients with Multiple Sclerosis.
- 21 Apr 2016 Results (n=354) presented at the 68th Annual Meeting of the American Academy of Neurology.
- 28 Sep 2015 According to Osmotica Pharmaceutical media release, the US FDA has accepted for filing a New Drug Application (NDA) for arbaclofen extended release tablet formulation (Ontinua) for alleviation of spasticity associated with multiple sclerosis.